Interleukin-35 suppresses antitumor activity of circulating CD8⁺ T cells in osteosarcoma patients

ABSTRACT

Purpose/Aim of the study: Interleukin (IL)-35 is a newly identified IL-12 cytokine family member and reveals immunosuppressive activity to CD8⁺ T cells in inflammation, infectious diseases, and cancers. However, little is known regarding IL-35 function in osteosarcoma. Thus, the aim of the current study was to investigate the regulatory function of IL-35 to CD8+ T cells in osteosarcoma.

Materials and methods: Thirty-five osteosarcoma patients and 20 healthy individuals were enrolled. Serum CD4⁺CD25⁺CD127^dim/– regulatory T cells (Tregs) and CD8⁺ T cells were purified. IL-35 concentration in serum and cultured supernatants was measured by enzyme-linked immunosorbent assay. Osteosarcoma cell line MG-63 cells and CD8⁺ T cells were stimulated with recombinant IL-35 in vitro, and modulatory function of IL-35 on these cells was assessed by investigation of cellular proliferation, cell cycle, apoptosis, and cytokine production.

Results: Serum IL-35 and Treg-secreting IL-35 were significantly elevated in osteosarcoma patients. IL-35 stimulation did not affect proliferation, apoptosis, or cell cycle of MG-63 cells. Purified peripheral CD8⁺ T cells from osteosarcoma patients revealed dysfunctional property, which presented as decreased mRNA expressions for perforin, granzyme B, and granulysin, as well as reduced cytolytic (direct lysis of target MG-63 cells) and noncytolytic (interferon-γ and tumor necrosis factor-α production) function in coculture systems. Moreover, IL-35 stimulation further diminished cytolytic and noncytolytic activity of CD8⁺ T cells from osteosarcoma patients.

Conclusions: The current data indicated that IL-35 contributed to CD8⁺ T-cell dysfunction and limited antitumor immune response in osteosarcoma.

KEYWORDS:

• Osteosarcoma
• interleukin-35
• CD8⁺ T cells
• immunoregulation
• antitumor

Disclosure statement

No potential conflict of interest was reported by the authors.